Gene Therapies For Rare Diseases Market Size, Share & Trends Analysis Report By Product (Zolgensma, Invossa K, Strimvelis, Neovasculgen, Glybera, Luxturna, Zynteglo, and Others), By Disease Type, Region And Segment Forecasts, 2023-2031.

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Gene Therapies for Rare Diseases Market Snapshot Chapter 4. Global Gene Therapies for Rare Diseases Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Penetration & Growth Prospect Mapping 4.6. Clinical Trial/Pipeline Analysis 4.7. Industry Analysis – Porter's Five Forces Analysis 4.8. Competitive Landscape & Market Share Analysis 4.9. Technology Advancement in Gene Therapies for Rare Diseases Market Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis 5.1. Product Type & Market Share, 2020 & 2028 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Product: 5.2.1. Zolgensma 5.2.2. Invossa K 5.2.3. Strimvelis 5.2.4. Neovasculgen 5.2.5. Glybera 5.2.6. Luxturna 5.2.7. Zynteglo 5.2.8. Others Chapter 6. Gene Therapies for Rare Diseases Market Segmentation 2: Application Estimates & Trend Analysis 6.1. Disease Type Analysis & Market Share, 2020 & 2028 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Disease Type: 6.2.1. Human Medicine 6.2.2. Human Medicine 6.2.3. Hemophilia 6.2.4. Duchenne Muscular Dystrophy 6.2.5. Achromatopsia 6.2.6. Cystic Fibrosis 6.2.7. Inherited Retinal Dystrophy 6.2.8. Fragile X Syndrome 6.2.9. Friedreich ataxia 6.2.10. Alpha-1 Antitrypsin Deficiency 6.2.11. Paroxysmal Nocturnal Hemoglobinuria 6.2.12. Retinitis Pigmentosa 6.2.13. Others Chapter 7. Gene Therapies for Rare Diseases Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America Gene Therapies for Rare Diseases Market revenue (US$ Million) estimates and forecasts by product, 2020-2028 7.1.2. North America Gene Therapies for Rare Diseases Market revenue (US$ Million) estimates and forecasts by Disease Type, 2020-2028 7.1.3. North America Gene Therapies for Rare Diseases Market revenue (US$ Million) estimates and forecasts by country, 2020-2028 7.1.3.1. U.S. 7.1.3.2. Canada 7.2. Europe 7.2.1. Europe Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, 2020-2028 7.2.2. Europe Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, 2020-2028 7.2.3. Europe Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, 2020-2028 7.2.3.1. Germany 7.2.3.2. Poland 7.2.3.3. France 7.2.3.4. Italy 7.2.3.5. Spain 7.2.3.6. UK 7.2.3.7. Rest of Europe 7.3. Asia Pacific 7.3.1. Asia Pacific Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, 2020-2028 7.3.2. Asia Pacific Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, 2020-2028 7.3.3. Asia Pacific Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, 2020-2028 7.3.3.1. China 7.3.3.2. India 7.3.3.3. Japan 7.3.3.4. Australia 7.3.3.5. Rest of Asia Pacific 7.4. Latin America 7.4.1. Latin America Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, (US$ Million) 7.4.2. Latin America Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, (US$ Million) 7.4.3. Latin America Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2028 7.4.3.1. Brazil 7.4.3.2. Rest of Latin America 7.5. MEA 7.5.1. MEA revenue Gene Therapies for Rare Diseases Market revenue (US$ Million) by product, (US$ Million) 2020-2028 7.5.2. MEA Gene Therapies for Rare Diseases Market revenue (US$ Million) by Disease Type, (US$ Million) 7.5.3. MEA Gene Therapies for Rare Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2028 Chapter 8. Competitive Landscape 8.1. Company Profiles 8.1.1. 4d Molecular Therapeutics, LLC 8.1.2. Abeona Therapeutics Inc. 8.1.3. Advaxis 8.1.4. Adverum Biotech 8.1.5. Aevi Genomic 8.1.6. Applied Genetic Technologies Corporation (AGTC) 8.1.7. Alcyone Lifesciences 8.1.8. Allife Medical Science and Technology 8.1.9. Amarna Therapeutics 8.1.10. American Gene Technologies 8.1.11. Amgen 8.1.12. Amicus Therapeutics 8.1.13. Anchiano Therapeutics 8.1.14. AnGes MG 8.1.15. Apic Bio 8.1.16. Armata Pharmaceuticals 8.1.17. Arrowhead 8.1.18. Arthrogen 8.1.19. Asklepios 8.1.20. Astellas 8.1.21. AVROBIO 8.1.22. BCM Families Foundation 8.1.23. Beijing Northland 8.1.24. Benitec 8.1.25. Biogen 8.1.26. BioMarin 8.1.27. Biosidus 8.1.28. bluebird bio 8.1.29. Boryung Group 8.1.30. Brain Neurotherapeuticsy Bio 8.1.31. Celsion Corporation 8.1.32. Chiesi 8.1.33. CRISPR Therapeutics 8.1.34. CSL Behring 8.1.35. Daewoong Pharma 8.1.36. Dicerna 8.1.37. Editas Medicine 8.1.38. Eiger BioPharmaceuticals 8.1.39. Enzo Therapeutics 8.1.40. Esteve 8.1.41. Evox Therapeutics 8.1.42. Expression Therapeutics 8.1.43. Fibrocell 8.1.44. Flexion Therapeutics, 8.1.45. Fortress Biotech 8.1.46. Freeline Therapeutics 8.1.47. Gene Biotherapeutics 8.1.48. Genenta Science 8.1.49. GeneQuine 8.1.50. Genethon 8.1.51. GenSight 8.1.52. Gilead 8.1.53. Gradalis 8.1.54. GSK 8.1.55. Hanugen 8.1.56. Helixmith 8.1.57. Herantis 8.1.58. ID Pharma 8.1.59. Immusoft 8.1.60. Inovio 8.1.61. Intellia Therapeutics 8.1.62. Intrexon 8.1.63. Juventas 8.1.64. Kolon Life Science 8.1.65. Krystal Biotech 8.1.66. Locana 8.1.67. LogicBio Therapeutics 8.1.68. Lysogene 8.1.69. Medigene 8.1.70. MeiraGTx 8.1.71. Miltenyi Biotec 8.1.72. Molecular Templates 8.1.73. Momotaro-Gene 8.1.74. Neuralgene 8.1.75. Novartis 8.1.76. OncoSec 8.1.77. Orchard Therapeutics 8.1.78. Oxford Biomedica 8.1.79. Pfizer 8.1.80. Prevail Therapeutics 8.1.81. PTC Therapeutics 8.1.82. REGENXBIO 8.1.83. Renova Therapeutics 8.1.84. Reyon Pharmaceutical 8.1.85. Roche 8.1.86. Rocket Pharma 8.1.87. Roivant 8.1.88. Sangamo Therapeutics 8.1.89. Sarepta Therapeutics 8.1.90. Seelos Therapeutics 8.1.91. Solid BioSciences 8.1.92. Sterna Biologicals 8.1.93. Sutura Therapeutics 8.1.94. SynerGene 8.1.95. Takara 8.1.96. Takeda 8.1.97. Talee Bio 8.1.98. Theragene Pharma 8.1.99. Transgene 8.1.100. Ultragenyx 8.1.101. uniQure 8.1.102. VBL Therapeutics 8.1.103. Vertex 8.1.104. Voyager Therapeutics 8.1.105. Xalud 8.1.106. Xenon 8.1.107. Ziopharm